Research & Applications
Major areas of scientific investigation into peptides and their potential.
Endocrinology & Metabolism
Peptide hormones such as insulin, GLP-1 receptor agonists, and growth hormone secretagogues have transformed the treatment of diabetes, obesity, and growth disorders. Research continues into longer-acting analogs and oral delivery systems.
Immunology & Infectious Disease
Antimicrobial peptides are being explored as alternatives to conventional antibiotics due to rising resistance. Additionally, peptide-based vaccines and immunomodulators are active areas of study.
Neuroscience & Pain
Neuropeptides and their receptors are targets for novel analgesics, treatments for neurodegenerative diseases, and psychiatric conditions. Research on orexins, substance P antagonists, and opioid peptides remains particularly active.
Oncology
Peptide-drug conjugates, tumor-homing peptides, and peptide vaccines are investigated for targeted cancer therapy. Their small size can allow better tumor penetration than antibodies in some contexts.
Cardiovascular & Renal
Natriuretic peptides, endothelin antagonists, and bradykinin-related pathways are studied for hypertension, heart failure, and kidney disease. Several peptide therapeutics are already in clinical use.
Challenges in Peptide Research
- Rapid degradation by proteases in the body
- Generally poor oral bioavailability
- Manufacturing scale-up and cost for longer or modified sequences
- Immunogenicity concerns with certain sequences or modifications
Advances in peptide chemistry (stapled peptides, macrocyclization, non-natural amino acids) and formulation technologies (lipid nanoparticles, permeation enhancers) are actively addressing these limitations.
Emerging Areas
Oral peptide delivery, peptide-drug conjugates for cancer, stapled peptides for intracellular targets, and AI-designed peptides are rapidly advancing fields. The pipeline includes candidates for Alzheimer's, infectious diseases, and rare disorders.
Notable Approved Peptide Therapeutics
| Drug | Indication | Key Feature |
|---|---|---|
| Insulin (various analogs) | Diabetes | First peptide drug; now rapid/long-acting versions |
| Semaglutide (Ozempic/Wegovy) | Type 2 diabetes, obesity | GLP-1 receptor agonist; once-weekly injectable or oral |
| Octreotide | Acromegaly, carcinoid syndrome | Somatostatin analog; longer half-life than native |
| Liraglutide (Victoza/Saxenda) | Diabetes, obesity | Daily GLP-1 analog with fatty acid modification |
| Teriparatide | Osteoporosis | Parathyroid hormone fragment; anabolic bone agent |
This is a small selection. Dozens more peptide and peptidomimetic drugs exist worldwide.